Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease

Kidney International

Volumn 74, Issue 6, 2008, Pages 782-790

  Keithi Reddy, Sai Ram ^a   Addabbo, Francesco ^b   Patel, Tejas V ^a   Mittal, Bharati V ^a   Goligorsky, Michael S ^b   Singh, Ajay K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Anemia; C reactive protein; Chronic kidney disease; Erythropoietin; Inflammation

Indexed keywords

AUTACOID; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; INTERLEUKIN 8; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; SERUM ALBUMIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; ERYTHROPOIESIS; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; UPREGULATION;

AGED; ANEMIA; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHRONIC DISEASE; CYTOKINES; EPOETIN ALFA; FEMALE; HEMATINICS; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; KIDNEY DISEASES; MALE; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 50849121381     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.245     Document Type: Article

References (49)

1. Jurkovitz CT, Abramson JL, Vaccarino LV et al. Association of high serum creatinine and anemia increases the risk of coronary events: results from the prospective community-based atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2003; 14: 2919-2925.
2. Singh AK, Szczech L, Tang KL et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-2098.
3. Drueke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
4. Smith KJ, Bleyer AJ, Little WC et al. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59: 538-548.
5. Ridker PM, Cook NR. Biomarkers for prediction of cardiovascular events. N Engl J Med 2007; 356: 1472-1473; author reply 1474-1475.
6. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007; 49: 2129-2138.
7. Tonelli M, Sacks F, Pfeffer M et al. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68: 237-245.
8. Lonnemann G, Engler-Blum G, Muller GA et al. Cytokines in human renal interstitial fibrosis. II. Intrinsic interleukin (IL)-1 synthesis and IL-1-dependent production of IL-6 and IL-8 by cultured kidney fibroblasts. Kidney Int 1995; 47: 845-854.
9. Lonnemann G, Shapiro L, Engler-Blum G et al. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int 1995; 47: 837-844.
10. Pradhan AD, Cook NR, Buring JE et al. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscl Thromb Vasc Biol 2003; 23: 650-655.
11. Haddy N, Sass C, Droesch S et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170: 277-283.
12. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
13. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006; 92: 441-444.
14. Simonini A, Moscucci M, Muller DW et al. IL-8 is an angiogenic factor in human coronary atherectomy tissue. Circulation 2000; 101: 1519-1526.
15. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109: II18-II26.
16. Addabbo F, Mallamaci F, Leonardis D et al. Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrol Dial Transplant 2007; 22: 3521-3526.
17. Iseki K, Tozawa M, Yoshi S et al. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14: 1956-1960.
18. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
19. Yeun JY, Levine RA, Mantadilok V et al. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476.
20. Kalantar-Zadeh K. Inflammatory marker mania in chronic kidney disease: pentraxins at the crossroad of universal soldiers of inflammation. Clin J Am Soc Nephrol 2007; 2: 872-875.
21. Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis 2001; 38: 1343-1350.
22. Panichi V, Migliori M, De Pietro S et al. C reactive protein in patients with chronic renal diseases. Ren Fail 2001; 23: 551-562.
23. Bemelmans MH, Gouma DJ, Buurman WA. Influence of nephrectomy on tumor necrosis factor clearance in a murine model. J Immunol 1993; 150: 2007-2017.
24. Ershler WB. Biological interactions of aging and anemia: a focus on cytokines. J Am Geriatr Soc 2003; 51: S18-S21.
25. Maccio A, Madeddu C, Massa D et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood 2005; 106: 362-367.
26. Davis D, Charles PJ, Potter A et al. Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. Br J Rheumatol 1997; 36: 950-956.
27. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
28. Sato Y, Takatsu Y, Kataoka K et al. Serial circulating concentrations of C-reactive protein, interleukin (IL)-4, and IL-6 in patients with acute left heart decompensation. Clin Cardiol 1999; 22: 811-813.
29. Hasper D, Hummel M, Kleber FX et al. Systemic inflammation in patients with heart failure. Eur Heart J 1998; 19: 761-765.
30. Yilmaz MI, Carrero JJ, Axelsson J et al. Low-grade inflammation in chronic kidney disease patients before the start of renal replacement therapy: sources and consequences. Clin Nephrol 2007; 68: 1-9.
31. Nemeth E, Valore EV, Territo M et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003; 101: 2461-2463.
32. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511.
33. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-2141.
34. Voulgari PV, Kolios G, Papadopoulos GK et al. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol 1999; 92: 153-160.
35. Krantz SB. Erythropoietin. Blood 1991; 77: 419-434.
36. Ludwig H, Fritz E, Kotzmann H et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990; 322: 1693-1699.
37. Kaltwasser JP, Kessler U, Gottschalk R et al. Effect of recombinant human erythropoietin and intravenous iron on anemia and disease activity in rheumatoid arthritis. J Rheumatol 2001; 28: 2430-2436.
38. Heeschen C, Aicher A, Lehmann R et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-1346.
39. Swaminathan S, Ahmed I, McCarthy JT et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145: 234-235.
40. De Marchi S, Cecchin E, Falleti E et al. Long-term effects of erythropoietin therapy on fistula stenosis and plasma concentrations of PDGF and MCP-1 in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1147-1156.
41. Desai A, Zhao Y, Lankford HA et al. Nitric oxide suppresses EPO-induced monocyte chemoattractant protein-1 in endothelial cells: implications for atherogenesis in chronic renal disease. Lab Invest 2006; 86: 369-379.
42. Stohlawetz PJ, Dzirlo L, Hergovich N et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000; 95: 2983-2989.
43. Anagnostou A, Lee ES, Kessimian N et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-5982.
44. Ammarguellat F, Llovera M, Kelly PA et al. Low doses of EPO activate MAP kinases but not JAK2-STAT5 in rat vascular smooth muscle cells. Biochem Biophys Res Commun 2001; 284: 1031-1038.
45. Ferrucci L, Guralnik JM, Woodman RC et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 2005; 118: 1288.
46. Jelkmann W. Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18: 555-559.
47. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. K Int 2005; 67: 1216-1233.
48. Gauldie J, Richards C, Harnish D et al. Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Ntl Acad Sci USA 1987; 84: 7251-7255.
49. Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.